A handout picture shared by MSN Laboratories. | Photo Credit: Special arrangement Drugmaker MSN Laboratories has launched its generic version of semaglutide under Semabest brand in the Indian market. Priced nearly 50% lower than the innovator drug, the product thus is bound to improve affordability and access for patients. Semabest available as a pre-filled pen for subcutaneous administration, the company said announcing the launch following Central Drugs Standard Control Organisation (CDSCO) approval. Published – April 17, 2026 10:36 pm IST Share this: Click to share on WhatsApp (Opens in new window) WhatsApp Click to share on Facebook (Opens in new window) Facebook Click to share on Threads (Opens in new window) Threads Click to share on X (Opens in new window) X Click to share on Telegram (Opens in new window) Telegram Click to share on LinkedIn (Opens in new window) LinkedIn Click to share on Pinterest (Opens in new window) Pinterest Click to email a link to a friend (Opens in new window) Email More Click to print (Opens in new window) Print Click to share on Reddit (Opens in new window) Reddit Click to share on Tumblr (Opens in new window) Tumblr Click to share on Pocket (Opens in new window) Pocket Click to share on Mastodon (Opens in new window) Mastodon Click to share on Nextdoor (Opens in new window) Nextdoor Click to share on Bluesky (Opens in new window) Bluesky Like this:Like Loading... Post navigation ‘Slaughtered like goats’: Despair and abandonment in South Sudan Harbour constituency: Sekarbabu bets on housing, traffic fix and education